Abstract
Aim: Making decisions about how to maintain general medical care and manage complications for patients in the last stage of advanced cancer is difficult. The benefits and necessity of antibiotic use in the last period of life are controversial. In this study, we aimed to investigate the frequency of antibiotic use in terminal stage cancer patients followed up with palliative care and died during their hospitalization.

Material and Methods: One hundred twenty-one patients from January 2015 to June 2020 were included.

Results: Among the 121 patients, 104 (86%) received antibiotics. Eighty-five (81.7%) patients received antibiotics until death. The mean duration of antibiotic treatment was 8.9 days. Antibiotic treatment was started 1 week before death in 88 (84.6%) of 104 patients who used antibiotics. The number of patients whose antibiotic treatment was discontinued was 3 (15.7%) in hospital wards and 16 (84.2%) in the intensive care unit.

Discussion: This is the first study on the frequency of antibiotic use in the end-of-life cancer patients in our country, and we found that the antibiotic prescription rate is high in dying cancer patients. It is questionable whether such care has positive effects on survival or quality of life. Guidelines on antibiotic use and discontinuation in patients with end-stage cancer should be developed.

Keywords
Palliative care; Cancer; Death; Dying; Infectious disease; Antibiotics
Introduction
Making decisions about how to maintain general medical care and manage complications for patients in the last stage of advanced cancer is extremely difficult for clinicians. The goal of palliative care is to help people die with dignity, but there may come a time when treatment can do more harm than good to patients. Infections are one of the most common causes of morbidity and mortality in cancer patients [1]. However, the clinical evidence for using or not using antibiotics in the end-of-life period is scarce, and the results are divergent [2-4]. Studies have shown that the frequency of antibiotic use in dying cancer patients varies greatly [5-7]. The use of antibiotics in dying cancer patients was found to be higher in hospitals than in hospice or palliative care centers [8-10].

Due to the lack of hospice care and the newly established palliative care centers, most of the terminal stage cancer patients still die in hospitals in our country. The aim of this study is to investigate the frequency of antibiotic use in patients with cancer in their last period of life.

Material and Methods
One hundred twenty-one terminal stage cancer patients who were followed up with palliative care and died in hospital from January 2015 to June 2020 were included. The term of terminal stage was used for patients who could not receive chemotherapy, radiotherapy or surgery due to reasons such as poor performance status or disease progression, and these patients received palliative care only for symptom control. Patient’s data were retrieved from medical records. Demographic data, including age, sex, primary cancer site and characteristics of infective episodes, including the site of infection, bacteriological results, use of second-line antibiotics, number of days of antibiotic use and stopping or not stopping antibiotics before death were recorded. The study was approved by the Acibadem University Ethics Committee.

Statistical Analyses
Data were analyzed using the statistical program Statistical Package for the Social Sciences (SPSS), version 20. We reported continuous variables as mean ± standard deviation. Categorical variables were defined as numbers (n) and percentages (%).

Results
There were 68 men and 53 women, and the mean patient age was 64.3±11.1 (29-87 years). Patient characteristics are shown in Table 1.

Among the 121 patients, 104 (86 %) received antibiotics. The mean duration from admission to death for all patients was 9.7±7.8 (1-30) days, and the mean duration of antibiotic use was 8.9±7.5 (1-30) days. Antibiotic treatment was started 1 week before death in 88 (84.6%) of 104 patients who used antibiotics. It was found that 80 (76.9%) of these patients lived less than 14 days. Eighty-five (81.7%) patients received antibiotics until death, only 19 (18.3%) had their antibiotic treatment discontinued before death. The mean duration of antibiotic withdrawal before death was 7.3 days. The number of patients whose antibiotic treatment was discontinued was 3 (15.7%) in the hospital wards and 16 (84.2%) in the intensive care unit. Sixty-four (52.8 %) patients died in the hospital wards, while 57 (47.1%) patients died in the intensive care unit. Culture was performed in 81 (77.8%) patients who received antibiotics. The culture was positive in 39 (48.1%) of these patients. In 18 (46.2%) patients, microorganisms were detected in blood culture, in 10 (25.6%) in urine, in 4 (10.3%) in sputum and respiratory secretions, and in 5 (12.8%) in pus. The infection episodes are shown in Table 2.

Table 1. Patient’s characteristics

| Characteristic | n | Percentage |
|----------------|---|------------|
| Total number of patients | 121 | 100% |
| Sex | | |
| Male/Female | 68/53 |
| Mean age: years (SD) | 64.3±11.1 |
| Primary cancer sites | | |
| Lung | 31 (25.6) |
| Colorectal | 26 (21.5) |
| Pancreatic-biliary system | 16 (13.2) |
| Upper gastrointestinal tract | 12 (9.9) |
| Gynecological | 10 (8.3) |
| Breast | 8 (6.7) |
| Gastrointestinal | 7 (5.8) |
| Others | 11 (9) |
| Median number of days on the hospital (days) | 9,7±7.8 |

Table 2. Infective episodes of the patients

| Characteristic | n=104 (100%) |
|----------------|---------------|
| Site of infection | | |
| Chest | 29 (26.9) |
| Urinary tract | 14 (13) |
| Gastrointestinal system | 16 (14.8) |
| Blood | 14 (13) |
| Skin/wound | 3 (2.8) |
| Others/unknown | 32 (29) |
| Bacteriological test | | |
| Yes | 81 (77.8) |
| No | 23 (22.2) |
| Culture positivity | | |
| Yes | 39 (48.1) |
| No | 42 (51.9) |
| Use of second-line antibiotics | | |
| Yes | 43 (41.3) |
| No | 61 (58.7) |
| Antibiotic started during the last week of life | 88 (84.6) |
| Receiving antibiotics at the end of life | 85 (81.7) |
| Antibiotic discontinued | 19 (18.3) |
| Mean duration of antibiotic use (days) | 8,9±7.5 |
| Outcomes | | |
| Survived >14 days | 24 (23) |
| Survived <14 days | 60 (77) |
Discussion

The use of antibiotics in near-death cancer patients poses a dilemma. Patients with advanced cancer are more susceptible to infection [11-13]. It is not possible to predict whether antibiotics will cure or whether withholding them will result in death [8]. Currently, there is no consensus regarding the use of antibiotics for patients in palliative care, and there is still uncertainty regarding ethical and legal issues such as stopping or interrupting antibiotic treatment [11-19]. Antibiotics for terminally ill patients may have some benefits, and although limited, they also have the potential to prolong life [10,11,16]. However, even if the risks of antibiotic use are low, they can be significant for frail patients. Antibiotics can also harm patients by prolonging the dying process [20-22].

Most data on antibiotic use in end-of-life patients comes from hospices and palliative care centers, hospitals data are limited. The frequency of prescribing antibiotics varies significantly between centers, but data show that antibiotic use in hospitals is higher than hospice and palliative care centers [5,7,9]. Oneschuk et al., showed that this rate was 58% in acute care hospitals, 52% in tertiary palliative care units, and 22% in hospice [9]. However, in the teaching hospitals, 83% of individuals with cancer in their terminal hospitalization were treated with antibiotics in a review including eight studies [11]. In another study examining cancer patients who died in hospital, 86.9% of patients used antibiotics, and 35.4% of these patients continued to receive antibiotics after a transition to comfort care [7]. In this study, we found that 86% of the patients who were followed up in the hospital for palliative care used antibiotics. While this rate is higher than in hospice or palliative care units, it is similar to hospital data, in accordance with the literature.

Differences in the ‘end-of-life’ decisions of physicians, family members, and patients, and differences in the organization of health systems may cause differences in antibiotic use across societies towards the end of life. While it was shown that 14% of the patients who were followed up in hospice with a primary diagnosis of cancer received antibiotic treatment in the last week of life in the USA [23], this rate was found to be 85.7% in a similar study from China [5]. While some doctors are concerned that the decision to discontinue antibiotics may risk shortening the life of the patient, others worry that this therapy may prolong the death process. We determined the antibiotic withdrawal rate before death as 18.2%. This rate is lower than antibiotic withdrawal rates in hospices in Western countries. Interestingly, this ratio was 15.7% in the hospital wards and 84.2% in the intensive care unit. Explanations for the difference in antibiotics withdrawal rates in the intensive care unit are unknown.

Study Limitations

There are several limitations to our study. First, our study was a single-centered study in a private hospital and may not reflect public hospitals practices. There are no large databases, and end-of-life care remarkably varies from hospital to hospital. Another limitation is the lack of data on decisions about using antibiotics in patients or whether they benefit from treatment. However, the main purpose of this study was not the reasons or benefit of using antibiotics.

Conclusion

To the best of our knowledge, this is the first study on the frequency of antibiotic use in the end-of-life cancer patients in our country.

Our study found that the antibiotic prescription rate is high in dying cancer patients. The main reasons for these high rates may be follow-up of the patients in the hospital instead of the hospice, the reluctance to stop the treatment initiated, cultural differences and the lack of guidelines on the use of antibiotics.

Scientific Responsibility Statement

The authors declare that they are responsible for the article's scientific content including study design, data collection, analysis and interpretation, writing, some of the main line, or all of the preparation and scientific review of the contents and approval of the final version of the article.

Animal and human rights statement

All procedures performed in this study were in accordance with the ethical standards of the institutional and/or national research committee and with the 1984 Helsinki declaration and its later amendments or comparable ethical standards. No animal or human studies were carried out by the authors for this article.

Funding: None

Conflict of interest

None of the authors received any type of financial support that could be considered a potential conflict of interest regarding the manuscript or its submission.

References

1. Abdel-Karim IA, Sammel RB, Prange MA. Causes of death at autopsy in an inpatient hospice program. J Palliat Med. 2007;10(4):894-8. DOI: 10.1089/jpm.2006.0240.
2. Chen LK, Chou YC, Hsu PS, Tsai SH, Hwang SJ, Wu BY, et al. Antibiotic prescription for fever episodes in hospice patients. Support Care Cancer. 2002;10:538-41. doi:10.1007/s00520-002-0377-9.
3. Oh DY, Kim JH, Kim DW, Im SA, Kim TY, Heo DS, et al. Antibiotic use during the last days of life in cancer patients. Eur J Cancer Care. 2006;15(1):74-9. DOI: 10.1111/j.1365-2354.2005.00603.x.
4. Stiel S, Knumm N, Pestinger M, Lindena G, Nauk F, Osterathe C, et al. Antibiotics in palliative medicine—Results from a prospective epidemiological investigation from the HOPE survey. Support Care Cancer. 2012;20:3235-33. DOI: 10.1007/ s00520-011-1084-1.
5. Cheng BH, Sham MM, Chan KY, Li CW, Au HY. Intensive palliative care for patients with hematological cancer dying in hospice: Analysis of the level of medical care in the final week of life. Am J Hosp Palliat Care. 2015;32(2):221-5. DOI: 10.1177/1049909113512412.
6. Merel SE, Meier CA, McKinney CM, Pottinger PS. Antimicrobial Use in Patients on a Comfort Care Protocol: A Retrospective Cohort Study. J Palliat Med. 2016; 19(11):1210-14. DOI: 10.1177/jp0099991114432625.
7. Albrecht JS, McGregor JC. Fromme EK, Bearden DT, Furano JP. A nationwide analysis of antibiotic use in hospice care in the final week of life. J Pain Symptom Manage. 2013;46(4):483–90.
8. Oneschuk D, Faisinger R, Demoissaz D. Antibiotic use in the last week of life in three different palliative care settings. J Palliat Care. 2002;18(1):25-8.
9. Rosenberg JH, Albrecht JS, Fromme EK, Noble BN, McGregor JC, Comer AC, et al. Antimicrobial Use for Symptom Management in Patients Receiving Hospice and Palliative Care: A Systematic Review. J Palliat Med. 2013;16(12):1568-74. DOI: 10.1089/jpm.2013.0276.
10. Nagy-Agren S, Haley H. Management of infections in palliative care patients with advanced cancer. J Pain Symptom Manage. 2002;24(1):64–70.
11. Pereira J, Watanabe S, Welch G. A retrospective review of the frequency of infections and patterns of antibiotic utilization on a palliative care unit. J Pain Symptom Manage. 1998;16(6):374-81.
12. Vietzta L, Kenner D, Sali A. Bacterial infections in terminally ill hospice patients. J Pain Symptom Manage. 2000;20(5):326-34.
13. Flowers CR, Seidenfeld J, Bow EJ, Karten C, Gleason C, Hawley DK, et al. Antimicrobial prophylaxis and outpatient management of fever and neutropenia in adults treated for malignancy. American Society of Clinical Oncology Practice Guidelines. J Clin Oncol. 2013; 203(16):794-810.
14. Taplitz RA, Kennedy EB, Bow EJ, Crews J, Gleason C, Hawley DK, et al. Antimicrobial prophylaxis for Adults Patients with Cancer-Related Immunosuppression. ASCO and IDSA Clinical Practice Guideline Update. J Clin Oncol. 2018; 203(16):3043-54.
End of life cancer patients, antibiotic use

guidelines from the Infectious Diseases Working Party (AGIHO) and Intensive Care Working Party (iCHOP) of German Society of Hematology and medical Oncology (DGHO). Ann Hematol. 2019;98(5):1051-69.

17. Chiu TY, Hu WY, Huang HL, Yao CA, Chen CY. Prevaling ethical dilemmas in terminal care for patients with cancer in Taiwan. J Clin Oncol. 2009;27:3964-8. DOI: 10.1200/JCO.2008.21.4643.

18. Ford PJ, Fraser TG, Davis MP, Kodish E. Anti-infective therapy at the end of life: Ethical decision-making in hospice-eligible patients. Bioethics. 2005;19:379–92.

19. Marcus EL, Clarfield AM, Moses AE. Ethical issues relating to the use of antimicrobial therapy in older adults. Clin Infect. Dis. 2001;33(10):1697-705. DOI: 10.1086/323757.

20. Mitchell SL, Shaffer ML, Loeb MB, Givens JL, Habtemariam D, Kiely DK, et al. Infection management and multidrug-resistant organisms in nursing home residents with advanced dementia. JAMA Intern Med. 2014;174(10):1660–7.

21. Kwak YG, Moon C, Kim ES, Kim BN. Frequent Prescription of Antibiotics and High Burden of Antibiotic Resistance among Deceased Patients in General Medical Wards of Acute Care Hospitals in Korea. PLoS One. 2016;11(1):e0146852. DOI: 10.1371/journal.pone.0146852.

22. Ahronheim JC, Morrison RS, Baskin SA, Morris J, Meier DE. Treatment of the dying in the acute care hospital. Advanced dementia and metastatic cancer. Arch Intern Med. 1996;156(18):2094–100.

23. Dwyer LL, Lau DT, Shega JW. Medications that Older Adults in Hospice Care in the United States Take, 2007. J Am Geriatr Soc. 2015;63(11):2282–9.

How to cite this article:
Semiha Urvay, Hatice Karagöz. Frequency of antibiotic use in the end-of-life cancer patients. Ann Clin Anal Med 2021;12(4):466-469